MonoSol Rx to Present at 2015 American Association of Pharmaceutical Scientists Annual Exposition Demonstrating PharmFilm as a Bioequivalent Delivery Platform for Sildenafil Citrate

WARREN, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, today announced that the Company will present a poster supporting MonoSol Rx's PharmFilm® oral soluble film as a bioequivalent delivery method of Sildenafil Citrate (Viagra) at the 2015 AAPS Annual Meeting and Exposition in Orlando, Fl., October 25-29.

The author will present a data poster supporting findings from a pilot human clinical trial. The trial compared two formulations of Sildenafil Citrate as an oral soluble film (OSF) against the traditional tablet form.

Logistical details are listed below:

Abstract M1196: "Bioequivalence of Two Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (VIAGRA) 100 mg Oral Tables in Healthy Male Volunteers"
Date: October 26, 2015
Location: Exhibit Hall WB1-WB2

Keith Kendall, CEO of MonoSol Rx, commented "By providing patients an attractive alternative to everyday drugs using PharmFilm technology, we further demonstrate that MonoSol Rx is a specialty pharmaceutical company whose products are at the forefront of research, development, and innovation."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.

CONTACT: MonoSol Rx Sanford Plachter splachter@monosolrx.com (908) 941-1900 The Ruth Group Lee Roth (investors) lroth@theruthgroup.com (646) 536-7012 Ashley Brown (media) abrown@theruthgroup.com (646) 536-7002

Source: MonoSol Rx